Fairvalue-Calculator Fairvalue-Calculator
EN DE

Shanghai ZJ Bio-Tech Co (688317) Fair Value & Analysis

Healthcare · CN · Market cap 3.3B CNY

Price¥16.36
Fair Value¥16.42
Upside+0.4%
Quality95/100
Evidence: Medium Range ¥15.83 – ¥17.00

Fair value as of: Jun 24, 2026

Analysis

Shanghai ZJ Bio-Tech Co (688317) currently trades at ¥16.36, while our model-based Fair Value estimate is ¥16.42 — implying the stock looks roughly 0.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Shanghai ZJ Bio-Tech Co., Ltd. engages in the research and development, production, and sale of molecular diagnostic reagents and instruments in China and internationally. It offers nucleic acid and real-time PCR kits, as well as consumables. The company was founded in 2005 and is based in Shanghai, China.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -84% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -7% Boston Scientific Corporation (B1SX34) -83% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Shanghai ZJ Bio-Tech Co (688317) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥16.42 versus a price of ¥16.36 — about +0% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 688317?
Our 21-model fair value for Shanghai ZJ Bio-Tech Co is ¥16.42 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥16.36.
What is the quality score of 688317?
Shanghai ZJ Bio-Tech Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.